Zydus Lifesciences Ltd rose for a third straight session today. The stock is quoting at Rs 984.6, up 1.03% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Zydus Lifesciences Ltd has dropped around 1.98% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has dropped around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 6.68 lakh shares today, compared to the daily average of 11.59 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 986.9, up 0.7% on the day. Zydus Lifesciences Ltd is up 55.45% in last one year as compared to a 18.09% gain in NIFTY and a 38.64% gain in the Nifty Pharma index.The PE of the stock is 22.53 based on TTM earnings ending September 24.Powered by Capital Market - Live

The key domestic benchmarks traded with major gains in the early afternoon trade. The Nifty traded above the 24,100 level. Auto shares advanced after declining in the past trading session. At 12:30 IST, the barometer index, the S&P BSE Sensex, jumped 678.24 points or 0.86% to 79,721.98. The Nifty 50 index gained 195.02 points or 0.82% to 24,109.20. In the broader market, the S&P BSE Mid-Cap index rose 0.07% and the S&P BSE Small-Cap index added 0.02%. The market breadth was positive. On the BSE, 2,006 shares rose and 1,792 shares fell. A total of 155 shares were unchanged. Derivatives: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, slipped 2.61% to 14.81. The Nifty 26 December 2024 futures were trading at 24,252.05 , at a premium of 142.85 points as compared with the spot at 24,109.20. The Nifty option chain for the 26 December 2024 expiry showed maximum Call OI of 42.1 lakh contracts at the 25,000 strike price. Maximum Put OI of 56.8 lakh contracts were seen at 24,000 strike price. Buzzing Index: The Nifty Auto index gained 0.78% to 23,315.80. The index slipped 1.48% in the past trading session. Mahindra & Mahindra (up 1.95%), Maruti Suzuki India (up 1.28%), Balkrishna Industries (up 0.97%), MRF (up 0.91%), TVS Motor Company (up 0.68%), Tata Motors (up 0.46%), Bajaj Auto (up 0.38%), Bharat Forge (up 0.30%) and Eicher Motors (up 0.20%) advanced. On the other hand, Exide Industries (down 1.41%), Apollo Tyres (down 0.83%) and Bosch (down 0.49%) edged lower. Stocks in Spotlight: Zydus Lifesciences advanced 2.02%. The company informed that it has received a demand order-in-original (O-I-O) of Rs 1.61 crore from the Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand, concerning the financial year 2017-18. PCBL shed 0.45%. The company said that the second and final phase of its specialty chemical capacity expansion at the Mundra plant in Gujarat has been successfully commissioned. IIFL Finance slipped 1.48%. IIFL Home Finance, a material subsidiary of the company has planned to raise up to Rs 500 crore through non-convertible debentures (NCDs) at a face value of Rs 1,000 each.Powered by Capital Market - Live

The issue pertains to the Input Tax Credit (ITC) carried forward through the TRAN-1 form. The company has been asked to pay a tax demand and penalty totaling Rs 1.61 crore. This demand relates to the alleged ITC carried forward through the TRAN-1 during FY 2017-18. The company clarified that it has not received any prior notice or show cause notice regarding the demand. The firm intends to challenge the order by filing an appeal. The company has stated that the demand will not have any material financial impact on its operations. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit increased 13.8% to Rs 911.20 crore in Q2 FY25 as against Rs 800.70 crore posted in Q2 FY24. Revenue from operations jumped 20.1% to Rs 5,113.60 crore in the quarter ended 30 September 2024. The scrip rose 2% to Rs 967.35 on the BSE. Powered by Capital Market - Live

Revenue from operations grew 19.87% year on year (YoY) to Rs 5,237 crore in the quarter ended 30 September 2024. Profit before tax was at Rs 1,270.9 crore in Q2 FY25, up 26.18% from Rs 1,007.2 crore reported in Q2 FY24. EBITDA stood at Rs 1,461.4 crore, registering the growth of 27.51% as compared to Rs 1,146.1 crore posted in same quarter last year. EBITDA margin improved to 27.9% in Q2 FY25 as against 26.2% in Q2 FY24. Research & Development (R&D) investments for the quarter stood at Rs 480 crore in Q2 FY25, up 50.23% from Rs 319.5 crore in Q2 FY24, which represented 9.2% of revenues. Additionally, organic capital expenditures (Capex) rose 39.54% YoY to Rs 301.7 in Q2 FY25. In terms of segment revenue, Formulations business grew by 9% YoY to Rs 1,456.9 crore. The business accounted for 28% of consolidated revenues. Branded business grew faster than the market with 10% YoY growth. Outpaced the market growth both in chronic and acute segments. Revenue from US Formulation business stood at Rs 2,416.8 crore in Q2 FY25, up 30% YoY. The business accounted for 47% of consolidated revenues. In constant currency terms, the business registered revenues of $ 288 million. Consumer Wellness generated Rs 487.5 crore in revenue, registering a 12% YoY growth. This segment accounted for 10% of the company's consolidated revenues. The growth was primarily led by 8.4% volume growth. Revenue from International Markets formulations business stood at Rs 538.9 crore, up 20% YoY. The business accounted for 11% of consolidated revenues. The business continued to deliver healthy growth with all major markets contributing to the growth during the quarter. The API business generated revenue of Rs 119.4 crore, down 15% YoY. This segment contributed 2% to the company's consolidated revenues. The Alliances and Others segment generated revenue of Rs 94.1 crore, registering a YoY growth of 178%. This segment contributed 2% to the company's consolidated revenues. During the quarter, the company has Received Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for the inspection of transdermal formulations facility located in Ahmedabad SEZ. Sharvil Patel, managing director, Zydus Lifesciences, said, Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core. Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The scrip declined 2.02% to Rs 949 on the BSE. Powered by Capital Market - Live

Net profit of Zydus Lifesciences rose 13.80% to Rs 911.20 crore in the quarter ended September 2024 as against Rs 800.70 crore during the previous quarter ended September 2023. Sales rose 20.08% to Rs 5113.60 crore in the quarter ended September 2024 as against Rs 4258.60 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5113.604258.60 20 OPM %28.5826.91 - PBDT1504.501191.40 26 PBT1270.901007.20 26 NP911.20800.70 14 Powered by Capital Market - Live

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live

Fludrocortisone Acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. The drug will be produced at the Group's manufacturing site at Moraiya, Ahmedabad. According to IQVIA MAT July 2024, Fludrocortisone acetate tablets generated annual sales of $19.9 million in the United States. The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The pharma company's consolidated net profit surged 30.64% to Rs 1,419.9 crore on 20.77% increase in revenue from operations to Rs 6,207.5 crore in Q1 FY25 over Q1 FY24. Shares of Zydus Lifesciences fell 0.19% to Rs 1,019 on the BSE. Powered by Capital Market - Live

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg (USRLD: Florinef Tablets, 0.1 mg). Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad. Fludrocortisone acetate tablets had annual sales of USD 19.9 mn in the United States (IQVIA MAT July 2024).Powered by Capital Market - Live

Zydus Lifesciences has formalized the Memorandum of Agreement (MoA) with Indian Council of Medical Research (ICMR) to initiate Phase 2 clinical trials of Desidustat in patients with Sickle Cell Disease. This Phase IIa, double blind, randomized, placebo controlled, parallel, multi-centre, proof-of-concept study, co-funded and co-monitored by INTENT, Indian National Clinical Trial and Education Network, Clinical Studies and Trial Unit, Division of Development Research, ICMR, will evaluate the efficacy and safety of Desidustat oral tablet for treatment of sickle cell disease. Proportion of patients with Hb response (defined as '' 1 g/dL increase in Hb from baseline) compared to placebo will be measured at week 4 and week 8 as the primary end-point. The trial will also evaluate Key Secondary Endpoints including Mean change in haemoglobin, proportion of patients requiring blood transfusions, proportion of patients experiencing vaso-occlusive crisis and mean change in percentage of HbSS. Pankaj Patel, Chairman of Zydus Lifesciences, mentioned that ''Public-private partnerships in the healthcare sector is essential to deliver novel drug to achieve the goals of the National Sickle Cell Anaemia Elimination Mission. The initiation of this study reaffirms hope for the 20 million Sickle Cell affected patients in the country for a high potential novel treatment.'' Powered by Capital Market - Live

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg (USRLD: Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg). Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. Paliperidone extended-release tablets will be produced at the Group's manufacturing site at SEZ, Ahmedabad. Paliperidone extended-release tablets had annual sales of USD XXX 47.1 in the United States (IQVIA MAT July 2024). Powered by Capital Market - Live